Lipoprotein(a)

Recent scientific evidence shows that the blood concentration of lipoprotein(a) (Lp(a)) is an important marker for the risk of developing heart disease. Nonetheless, Lp(a) measurements are not widely available and are seldom used in routine clinical practice. A traditional lipid panel measures total cholesterol, triglycerides,and high-density lipoprotein cholesterol (HDL-C) The numbers are then used to … Read more

Evolocumab (Repatha) for Heart Disease – The FOURIER Trial – Success or Failure?

The eagerly awaited results of the FOURIER trial were recently presented at the Annual Meeting of the American College of Cardiology (ACC) in Washington DC and simultaneously published in the New England Journal of Medicine (1). The goal of FOURIER was to evaluate the efficacy and safety of evolocumab (Repatha), a PCSK9 inhibitor, among subjects with elevated risk … Read more

GLAGOV – The Lipid Hypothesis Gains Ground

The results from the recent GLAGOV trial suggest that aggressive lowering of LDL-cholesterol with a PCSK9-inhibitor on top of statin therapy in patients with coronary artery disease may reduce atherosclerotic plaque burden. Although these results provide support for the lipid hypothesis and may have significant implications for the future of cardiovascular medicine, our eyes are still on safety and … Read more